<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">95010</article-id><article-id pub-id-type="doi">10.7554/eLife.95010</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.95010.3</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Short Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>Unraveling the power of NAP-CNB’s machine learning-enhanced tumor neoantigen prediction</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mendez-Perez</surname><given-names>Almudena</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Acosta-Moreno</surname><given-names>Andres M</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Wert-Carvajal</surname><given-names>Carlos</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Ballesteros-Cuartero</surname><given-names>Pilar</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Sánchez-García</surname><given-names>Ruben</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Macias</surname><given-names>Jose R</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Sanz-Pamplona</surname><given-names>Rebeca</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Alemany</surname><given-names>Ramon</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Oscar Sorzano</surname><given-names>Carlos</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Munoz-Barrutia</surname><given-names>Arrate</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1573-1661</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Veiga</surname><given-names>Esteban</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-7333-2466</contrib-id><email>eveiga@cnb.csic.es</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/015w4v032</institution-id><institution>Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas</institution></institution-wrap><addr-line><named-content content-type="city">Madrid</named-content></addr-line><country>Spain</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03ths8210</institution-id><institution>Departamento de Bioingenieria, Universidad Carlos III de Madrid, Leganés</institution></institution-wrap><addr-line><named-content content-type="city">Madrid</named-content></addr-line><country>Spain</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/052gg0110</institution-id><institution>University of Oxford, Department of Statistics &amp; XChem</institution></institution-wrap><addr-line><named-content content-type="city">Oxford</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01j1eb875</institution-id><institution>Catalan Institute of Oncology (ICO), Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat</institution></institution-wrap><addr-line><named-content content-type="city">Barcelona</named-content></addr-line><country>Spain</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03fyv3102</institution-id><institution>University Hospital Lozano Blesa, Aragon Health Research Institute (IISA), ARAID Foundation, Aragon Government</institution></institution-wrap><addr-line><named-content content-type="city">Zaragoza</named-content></addr-line><country>Spain</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01nv2xf68</institution-id><institution>Procure Program, Institut Català d'Oncologia-Oncobell Program, Catalan Institute of Oncology (ICO), Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat</institution></institution-wrap><addr-line><named-content content-type="city">Barcelona</named-content></addr-line><country>Spain</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Zaidi</surname><given-names>Neeha</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00za53h95</institution-id><institution>Johns Hopkins University</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>El-Deiry</surname><given-names>Wafik S</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05gq02987</institution-id><institution>Brown University</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>11</day><month>03</month><year>2025</year></pub-date><volume>13</volume><elocation-id>RP95010</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2024-01-07"><day>07</day><month>01</month><year>2024</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2023-11-22"><day>22</day><month>11</month><year>2023</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2023.11.22.568042"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-06-05"><day>05</day><month>06</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.95010.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-02-12"><day>12</day><month>02</month><year>2025</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.95010.2"/></event></pub-history><permissions><copyright-statement>© 2024, Mendez-Perez et al</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Mendez-Perez et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-95010-v1.pdf"/><abstract><p>In this study, we present a proof-of-concept classical vaccination experiment that validates the in silico identification of tumor neoantigens (TNAs) using a machine learning-based platform called NAP-CNB. Unlike other TNA predictors, NAP-CNB leverages RNA-seq data to consider the relative expression of neoantigens in tumors. Our experiments show the efficacy of NAP-CNB. Predicted TNAs elicited potent antitumor responses in mice following classical vaccination protocols. Notably, optimal antitumor activity was observed when targeting the antigen with higher expression in the tumor, which was not the most immunogenic. Additionally, the vaccination combining different neoantigens resulted in vastly improved responses compared to each one individually, showing the worth of multiantigen-based approaches. These findings validate NAP-CNB as an innovative TNA identification platform and make a substantial contribution to advancing the next generation of personalized immunotherapies.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>vaccination</kwd><kwd>antigen identification</kwd><kwd>cancer</kwd><kwd>machine learning-based platform</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004837</institution-id><institution>Ministerio de Ciencia e Innovación</institution></institution-wrap></funding-source><award-id>PID2020-116393RB-I00</award-id><principal-award-recipient><name><surname>Veiga</surname><given-names>Esteban</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100011033</institution-id><institution>Agencia Estatal de Investigación</institution></institution-wrap></funding-source><award-id>10.13039/501100011033</award-id><principal-award-recipient><name><surname>Veiga</surname><given-names>Esteban</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100018779</institution-id><institution>Fundación Fero</institution></institution-wrap></funding-source><award-id>BFERO2020.04</award-id><principal-award-recipient><name><surname>Veiga</surname><given-names>Esteban</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004837</institution-id><institution>Ministerio de Ciencia e Innovación</institution></institution-wrap></funding-source><award-id>FPU18/03199JMGG</award-id><principal-award-recipient><name><surname>Mendez-Perez</surname><given-names>Almudena</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>NAP-CNB, a machine learning platform, accurately identifies tumor neoantigens, where higher tumor expression correlates with optimal antitumor activity, and multiantigen vaccination enhances immune responses.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>A new window of hope to treat previously intractable tumors is emerging through immunotherapies (<xref ref-type="bibr" rid="bib6">Chen and Mellman, 2013</xref>). However, the response rates of these therapies remain low and relapses are common (<xref ref-type="bibr" rid="bib11">Kalbasi and Ribas, 2020</xref>; <xref ref-type="bibr" rid="bib12">Novello et al., 2023</xref>). Moreover, the severe undesired side effects induce many patients to abandon the treatments (<xref ref-type="bibr" rid="bib11">Kalbasi and Ribas, 2020</xref>), highlighting the urgent need for more specific novel therapies.</p><p>In this regard, the main challenges for most anticancer immunotherapies are the identification of tumor-specific antigens (neoantigens) (<xref ref-type="bibr" rid="bib14">Schumacher and Schreiber, 2015</xref>) to avoid undesired side effects and the development of multiantigen-based treatments with combined therapies to prevent tumor relapses (<xref ref-type="bibr" rid="bib4">Cable et al., 2021</xref>). A possible strategy to accelerate the search for neoantigens and lower the cost of the therapy is to sequence the cancer cells using next-generation sequencing techniques and find mutations using bioinformatics tools. Finally, it tries to predict which of the mutations will be more likely to cause an immune response, i.e., neoantigen prediction. This area is relatively unexplored with only a few algorithms available (<xref ref-type="bibr" rid="bib2">Boegel et al., 2019</xref>). The need to validate the algorithmic results has already been recognized as one of the critical steps of this approach (<xref ref-type="bibr" rid="bib16">Vitiello and Zanetti, 2017</xref>) and this work specifically addresses it. Algorithmic proposals using deep learning have only started to appear and most of them clearly outperform the standard approaches (<xref ref-type="bibr" rid="bib3">Bulik-Sullivan et al., 2018</xref>; <xref ref-type="bibr" rid="bib18">Wu et al., 2019</xref>). Finding neoantigens in every cancer patient will be fundamental for personalized antitumor immunotherapies (<xref ref-type="bibr" rid="bib15">Tran et al., 2017</xref>).</p><p>We previously developed an easy-to-use platform (NAP-CNB) (NAP stands for neoantigen prediction) that allows to identify tumor neoantigens rapidly (<xref ref-type="bibr" rid="bib17">Wert-Carvajal et al., 2021</xref>). NAP-CNB predicts putative neoantigens employing exclusively RNA-seq reads (<xref ref-type="bibr" rid="bib17">Wert-Carvajal et al., 2021</xref>). The tool uses a long short-term memory-based neural network to rank mutations according to their estimated major histocompatibility complex (MHC) I affinity. NAP-CNB harnesses the suitability of recurrent neural networks for sequential problems to offer high accuracy in affinity binding prediction. Hence, NAP-CNB provides an integrated and resource-efficient pipeline for in silico classification of MHC I neoepitopes. In contrast with other tools (<xref ref-type="bibr" rid="bib1">Bjerregaard et al., 2019</xref>; <xref ref-type="bibr" rid="bib8">Duan et al., 2014</xref>; <xref ref-type="bibr" rid="bib9">Hasegawa et al., 2020</xref>; <xref ref-type="bibr" rid="bib10">Hundal et al., 2016</xref>), NAP-CNB is entirely automatic and freely available online.</p><p>We found NAP-CNB to be comparable or superior to other state-of-the-art methods of murine immunogenicity prediction, like NetH2pan (<xref ref-type="bibr" rid="bib7">DeVette et al., 2018</xref>) or MHCflurry 2.0 (<xref ref-type="bibr" rid="bib13">O’Donnell et al., 2020</xref>), in blind benchmarking. NAP-CNB presents an area under the curve of 95% for H-2K<sup>b</sup> typings and a high positive predictive value. The results improved with post-processing which consists of a majority voting method of an ensemble of sequences presenting single amino acid substitutions. Post-processing offers a more robust scoring by substituting each amino acid for its most similar one and then classifying the ensemble as the most repeated class.</p></sec><sec id="s2" sec-type="results|discussion"><title>Results and discussion</title><p>In this work, we analyze in vivo the tumor neoantigen (TNA) predictive capabilities of NAP-CNB platform using the well-known murine B16 F10 melanoma as a model. For that, we synthesized the peptides corresponding to predicted TNA, used them to vaccinate mice, and analyzed the effectivity against tumor development.</p><p>In silico analysis of the B16 F10 melanoma gene expression showed several putative TNA (<xref ref-type="bibr" rid="bib17">Wert-Carvajal et al., 2021</xref>) with different scores (predicted probability to be a TNA) and distinct gene expression quantified as fragments per kilobase million. We chose for peptide synthesis three top-scored TNA peptides (<xref ref-type="fig" rid="fig1">Figure 1A</xref>); *Pnp (low expression), *Adar (very low expression), *Lrrc28 (low expression). The * indicates that they are the mutated version, as indicated in the figure. The bottom-scored peptide, *Herc6 (high expression), therefore, predicted to not induce any immune reaction against the tumor, was chosen as a negative control. In addition, and in order to test whether the post-processing process offers some advantage, a top-scored peptide, *Wiz (high expression), revealed after post-processing was also synthesized (<xref ref-type="fig" rid="fig1">Figure 1A</xref>).</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Vaccination-induced immune responses.</title><p>(<bold>A</bold>) Putative B16 tumor neoantigen (TNA) identified by using the NAP-CNB platform ranked by scores of peptide sequences for a complete 12mer sequence. The TNA sequence, the mutation exclusive to tumor cells (in red), and gene name are shown. The gene expression is quantified as fragments per kilobase million (FPKM). The TNA score is also indicated. (<bold>B</bold>) Scheme of immunization. Two doses of peptides emulsified in Freund’s adjuvant were subcutaneously (s.c.) injected, separated by 14 days. 14 days after the last dose the efficacy of the vaccine was analyzed by enzyme-linked immunosorbent spot (ELISpot) and intracellular cytokine staining (ICS) assays. (<bold>C</bold>) ELISpot analysis of interferon-gamma (IFNγ)-producing T-cell effectors from mice vaccinated with the indicated mutated peptides. The upper images show the response of non-vaccinated (phosphate-buffered saline [PBS]) animals after stimulation with the indicated peptides, the bottom images show the response of the animals vaccinated (vaccin) with the indicated peptides after restimulation with the same peptides. It is shown duplicates from representative animals. (<bold>D</bold>) As in C but showing the mean and sd of 5 mice/group. Asterisks indicate statistically significant differences analyzed by one-way ANOVA (* represent p&lt;0.05, **p&lt;0.005, ***p&lt;0.0005). (<bold>E</bold>) ICS analysis of CD8<sup>+</sup> T-cells expressing tumor necrosis factor alpha (TNFα), perforin, or CD107a from mice vaccinated with the indicated mutated peptides: *Pnp (black triangle), *Adar (black circle), *Lrrc28 (black square), *Wiz (black rhombus), *Herc6 (gray circle), and Trp2 (green circle). The mean of the ratio of vaccinated divided by unvaccinated is shown, as the 95% confidence intervals. Intervals that do not include 1 and are therefore statistically significant are marked with *. 5 mice/group were used.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Original data of <xref ref-type="fig" rid="fig1">Figure 1C-E</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-95010-fig1-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95010-fig1-v1.tif"/></fig><sec id="s2-1"><title>Immunogenicity analysis</title><p>To analyze the immunogenicity of the predicted TNAs, we employed immunocompetent C57BL/6J mice as the recipient model. These mice were vaccinated with individual synthetic peptides *Pnp, *Adar, *Lrrc28, *Wiz, and *Herc6, the latter serving as a putative negative control. In all cases, peptides were emulsified in Freund’s adjuvant. A second vaccination boost was injected 2 weeks after the first inoculation. Four weeks after the first inoculation the immunogenicity of the predicted antigens was tested (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). A group of mice were treated with phosphate-buffered saline (PBS)+adjuvant (non-vaccinated control).</p><p>We assessed specific cellular responses against the predicted TNAs using an enzyme-linked immunosorbent spot (ELISpot) assay (<xref ref-type="fig" rid="fig1">Figure 1C and D</xref>). Compared to the control group immunized with *Herc6, all vaccinated groups displayed notably elevated levels of interferon-gamma (IFNγ)-secreting cells targeting TNAs. Notably, *Wiz vaccination yielded a comparatively weaker immune response. This experiment further validates the predicted non-immunogenic nature of the *Herc6 mutation.</p><p>Furthermore, we evaluated the immunogenic potential of the predicted TNAs through intracellular cytokine staining (ICS) (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). The CD8<sup>+</sup> T-cell population from vaccinated mice was activated by presenting the TNAs on splenocytes, and the production of tumor necrosis factor alpha (TNFα), perforin, and CD107a was analyzed via flow cytometry. Vaccination with all TNAs significantly induced the expression of at least one of the specified proteins after specific stimulation. Additionally, we included a well-established positive control, tyrosinase-related protein-2 (Trp2), a well-known tumor-associated antigen that induces potent cellular responses (<xref ref-type="bibr" rid="bib5">Castle et al., 2012</xref>). As predicted, vaccination with *Herc6 did not elicit immunogenic responses.</p><p>These data show that silico-predicted TNAs by NAP-CNB induce robust immune responses following immunization in mice.</p></sec><sec id="s2-2"><title>In vivo antitumor implantation assays</title><p>The antitumor immunogenicity of predicted TNAs was further assessed using immunocompetent C57BL/6J mice, vaccinated with each synthetic peptide or with a peptide mixture containing *Pnp, *Adar, and *Lrrc28, in all cases emulsified in Freund’s adjuvant. A second vaccination boost was injected 2 weeks after the first inoculation and 2 weeks before tumor implantation (B16 F10 melanoma; see experimental scheme in <xref ref-type="fig" rid="fig2">Figure 2A</xref>). Tumor size, as well as overall survival, was monitored over time.</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Antitumor activity of vaccination with predicted tumor neoantigen (TNA).</title><p>(<bold>A</bold>) Scheme of immunization. Two doses of peptides emulsified in Freund’s adjuvant were subcutaneously (s.c.) injected, separated by 14 days. 14 days after the last dose the B16 F10 melanoma cells were injected s.c. in the mid-right flank of C57BL/6J host mice and the tumor size over time was analyzed using a dial caliper. (<bold>B–I</bold>) Tumor growth on non-vaccinated (B) or vaccinated mice with the indicated peptide (<bold>C–I</bold>) (or peptide mix (<bold>H</bold>)), monitored every 1–3 days. Each line corresponds to the tumor size in one animal. The median of the tumors in non-vaccinated (phosphate-buffered saline [PBS]) and vaccinated with Trp2 (positive control) are shown as dashed lines in gray and green color, respectively. Mice with tumors≥900 mm<sup>3</sup> were sacrificed. Following the rules of our ethical committee, animals presenting ulcers were also sacrificed. (<bold>J</bold>) Percentage of animals showing tumors with a volume≤100 mm<sup>3</sup> 15 days after implantation. 4 mice/group were used.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Original data of <xref ref-type="fig" rid="fig2">Figure 2B-J</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-95010-fig2-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95010-fig2-v1.tif"/></fig><p>The implanted tumor exhibited robust growth in the control group of non-vaccinated animals (PBS; <xref ref-type="fig" rid="fig2">Figure 2B</xref>). 15 days after implantation, all animals in this group displayed tumors with a volume exceeding 100 mm³. All animals died 22 days after tumor implantation (<xref ref-type="fig" rid="fig3">Figure 3A and B</xref>). Vaccination with the positive control, Trp2, showed immune responses against B16 F10 detected as slower tumor growth (<xref ref-type="fig" rid="fig2">Figure 2C</xref>) and incremented survival rates (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). The median of the tumor growth in control unvaccinated mice (PBS) and vaccinated with Trp2 (positive control) are shown to compare the antitumor response of animals vaccinated with the indicated peptides. As expected, the immunization with *Herc6, in silico predicted as non-immunogenic, did not result in any positive outcome either in tumor growth (<xref ref-type="fig" rid="fig2">Figure 2D</xref>) or in survival rate (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). Vaccination with *Pnp and *Lrrc28 elicited irregular antitumor responses (<xref ref-type="fig" rid="fig2">Figure 2E and G</xref>) with some mice showing excellent responses and other behaving similar to the negative control. These vaccinations showed slightly (not significant) incremented survival rates compared to control (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). Vaccination with *Adar (the less expressed TNA; <xref ref-type="fig" rid="fig1">Figure 1A</xref>) did not reduce the tumor growth (<xref ref-type="fig" rid="fig2">Figure 2F</xref>) nor show any survival improvement (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). However, the vaccination with a mixture of the three predicted TNA (Pnp, Adar, Lrrc28) induced a strong antitumor response, comparable and even better than that observed with the positive control, Trp2 (<xref ref-type="fig" rid="fig2">Figure 2H</xref>), resulting in a significantly increased survival (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). In the same regard, the response against tumors in animals vaccinated with *Wiz (predicted TNA after post-processing and highly expressed) alone also elicited a powerful antitumor response (<xref ref-type="fig" rid="fig2">Figure 2I</xref>) with considerably improved survival (<xref ref-type="fig" rid="fig3">Figure 3A</xref>).</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Survival curves of vaccinated mice.</title><p>(<bold>A, B</bold>) Kaplan-Meier survival curves of mice vaccinated with the indicated tumor neoantigen (TNA) peptides and challenged with B16 F10 melanoma.</p><p>Comparison of survival curves has been performed using the log-rank (Mantel-Cox) test. The significant p values comparing the control (phosphate-buffered saline [PBS]) group with each other group are indicated and * represents p&lt;0.05. 4 mice/group were used.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Original data of <xref ref-type="fig" rid="fig3">Figure 3</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-95010-fig3-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95010-fig3-v1.tif"/></fig><p>Additionally, as a measure of the vaccination effectiveness, it is shown the percentage of mice with tumors remained smaller than 100 mm<sup>3</sup>, 15 days after implantation (<xref ref-type="fig" rid="fig2">Figure 2J</xref>). Non-vaccinated animals or animals vaccinated with *Herc6 or *Adar show unsuccessful therapies. Vaccination with *Pnp or *Lrrc28 presented a successful rate of 75% and 50% respectively, and the maximum effectiveness, 100% of animals, was observed in animals vaccinated with Trp2, *Wiz, or a peptide mixture (*Pnp, *Adar, and *Lrrc28).</p><p>Together, these data show that pure in silico approaches based on machine learning algorithms are able to identify TNAs that induce strong antitumor protection, which is the major bottleneck for most immunotherapies. The rapid identification of tumor neoantigens would allow to target/attack tumors non-treatable today and will vastly improve current immunotherapies, representing a giant step forward in the global anticancer fight. In this context, we demonstrate that the algorithms running in NAP-CNB platform effectively identify TNA that can be used as anticancer targets. The proof-of-concept experiments presented herein significantly bolster the prospects of translating TNA identification into practical applications for personalized cancer treatments within society.</p><p>Our findings also offer valuable insights for shaping future antitumor interventions. From a pragmatic standpoint, prioritizing TNAs with higher expression levels in the tumor, even if they elicit a comparatively weaker immunogenic response, appears to be a more promising approach. Our data confirm that employing a multiantigen therapy, targeting various tumor epitopes simultaneously, holds significant potential in averting immune escape. This underscores the importance of advancing TNA-based immunotherapy treatments against cancer within the framework of personalized medicine.</p></sec></sec><sec id="s3" sec-type="materials|methods"><title>Materials and methods</title><sec id="s3-1"><title>Peptides</title><p>*Pnp (SLITNKVVMEYENLEKANHM), *Adar (LVPLSQAWTHPPGVVNPDSC), *Lrrc28 (EPMFTFVYPTIFPLRETPMA), *Herc6 (SLVKKWRAAKKRKDREGAKR), *Wiz (TASPPPTARMMFSGLATPSL), and *Trp2 (PQIANCSVYDFFVWLHYYSV) were used for mice immunization. These peptides were synthesized at the proteomics unit from CNB-CSIC. The peptides were synthesized using the stepwise solid-phase peptide synthesis method performed on an automated peptide synthesizer (Multipep, Intavis, Köln, Germany). The amino acid polymerization was carried out using the standard Fmoc (<italic>N</italic>-(9-fluorenyl) methoxycarbonyl) chemistry and PYBOP/<italic>N</italic>-methylmorpholine as coupling activation reagents. The Fmoc-derivatized amino acid monomers and the preloaded resins used as support were obtained from Merck. Once synthesized the peptides were cleaved from the resin with a standard scavenger-containing trifluoroacetic acid (TFA)-water cleavage solution and precipitated by addition to cold ether. The crude peptides were purified by reverse-phase chromatography on a semi-preparative HPLC system (Jasco, Tokio, Japan) equipped with a C18 reversed-phase column (Scharlab, Barcelona, Spain). A linear gradient from 5% to 60% solvent B (0.05% TFA in 95% acetonitrile) in solvent A (0.05% TFA in water) was applied for 20 min. The chosen fractions were analyzed in a MALDI TOF 4800 mass spectrometer (Applied Biosystems, Framingham, MA, USA) and those containing the peptide were lyophilized. The peptides were then reconstituted to a concentration of 1 mg/ml in sterile PBS and preserved at –80°C.</p></sec><sec id="s3-2"><title>Mouse immunization</title><p>Equal volumes of immunogens and Freund’s adjuvant (Imject Freund’s Complete Adjuvant (FCA) for the first dose and Imject Freund’s Incomplete Adjuvant (FIA) for the second dose, from Thermo Scientific) were mixed with a double-hub needle until a thick emulsion developed. The final immunogen concentration in the mixtures was 50 µg/100 µl. C57BL/6J mice were divided into eight groups and were subcutaneously (s.c.) immunized in the left flank with PBS (group 1) or with 100 µl of the emulsions containing *Trp2 peptide (group 2), *Herc6 peptide (group 3), *Pnp peptide (group 4), Adar peptide (group 5), *Lrrc28 peptide (group 6), *Pnp, *Adar, and *Lrrc28 peptides mixture (group 7), or *Wiz peptide (group 8). Immunizations were performed at day 0 (with FCA) and day 14 (with FIA). At day 28, the efficacy of the vaccine was analyzed by ELISpot and ICS assays, and an antitumor experiment was performed.</p></sec><sec id="s3-3"><title>ELISpot assay</title><p>The ELISpot assay was used to detect *Pnp, *Adar, *Lrrc28, *Herc6, and *Wiz specific IFNγ-secreting cells. 96-well nitrocellulose-bottom plates pre-coated with anti-mouse IFNγ monoclonal antibody were purchased from Mabtech. The plates were blocked with RPMI-10% fetal bovine serum (FBS) for at least 30 min. After spleen processing, 3×10<sup>5</sup> splenocytes per condition were restimulated with 1 μg/ml of the corresponding peptide pool or with RPMI-10% FBS. The plates were incubated with the peptides for 48 hr at 37°C in 5% CO<sub>2</sub> atmosphere, washed five times with PBS, and incubated with 1 μg/ml of the biotinylated anti-mouse IFNγ monoclonal antibody R4-6A2 (Mabtech) diluted in PBS-0.5% FBS for 2 hr at room temperature. The plates were then washed five times with PBS and a 1:1000 dilution of alkaline phosphatase (ALP)-conjugated streptavidin (Mabtech) was added. After 1 hr at room temperature, it was washed five times with PBS, and finally developed by adding the ready-to-use substrate solution BCIP/NBT-plus 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium chloride (Mabtech). The reaction was stopped by washing the plate with abundant water. Once it was dry, the spots were counted using the ELISpot Reader System - ELR02 - plate reader 651 (AID Autoimmun Diagnostika GmbH) with the aid of AID ELISpot reader system software (Vitro).</p></sec><sec id="s3-4"><title>ICS assay</title><p>The different CD8<sup>+</sup> T-cell adaptive immune responses were analyzed by ICS as follows. After spleen processing, 4×10<sup>6</sup> fresh splenocytes (depleted of red blood cells) were seeded on M96 plates and stimulated for 12 hr in complete RPMI 1640 medium supplemented with 10% FBS containing 1 μl/ml Brefeldin A (BD Biosciences) to inhibit cytokine secretion, 1 μl/ml monensin 1× (eBioscience), anti-CD107a-FITC (BD Biosciences), and the peptides *Pnp, *AdaR, *Lrrc28, *Herc6, *Wiz, or Trp2 (1 μg/ml). Cells were then washed, stained for surface markers, fixed (eBioscience IC Fixation Buffer), permeabilized (eBioscience Permeabilization Buffer), and stained intracellularly with the appropriate fluorochromes. The fluorochrome-conjugated antibodies used for functional analyses were CD3-brilliant violet (BV)-510 (BD Biosciences), CD8 allophycocyanin (APC)-EFluor780 (eBioscience), PERFORIN-APC (BioLegend), and TNFα-Pacific Blue (BioLegend). Cells were acquired with an LSR-II flow cytometer (BD Biosciences). Analyses of the data were performed with the FlowJo software version 10.4.2 (Tree Star).</p></sec><sec id="s3-5"><title>Cells</title><p>B16 F10 melanoma cell line was obtained from American Type Culture Collection (ATCC, Manassas, VA, USA) and maintained in high glucose Dulbecco’s Modified Eagle’s Medium (Gibco-Life Technologies) supplemented with 10% FBS. Cell cultures were maintained at 37°C in a humidified incubator containing 5% CO<sub>2</sub>.</p></sec><sec id="s3-6"><title>Antitumor experiment</title><p>At day 28 after mouse immunization, B16 F10 cells (4×10<sup>5</sup>) were s.c. injected into the mid-right flank of C57BL/6J recipient mice. Tumor growth was measured every 2–3 days with a dial caliper, and the volume was determined by ½(length×width<sup>2</sup>).</p></sec><sec id="s3-7"><title>Statistical procedures</title><p>One-way ANOVA with Dunnett correction for multiple testing was used for ELISpot analysis to establish the differences within the different groups. We analyzed the ICS results by building a bootstrap distribution based on the ratio of the percentage of specific cell types between the vaccinated and unvaccinated groups. Subsequently, we determined the centered 95% confidence interval. For statistical analysis of the overall survival in the antitumor experiment, log-rank (Mantel-Cox) statistical test was performed on day 24. The statistical significances are indicated as follows: *, p&lt;0.05; **, p&lt;0.005; ***, p&lt;0.001. Statistical analysis was performed using Prism Software.</p></sec><sec id="s3-8"><title>Ethical statement</title><p>Female C57BL/6J mice (6–8 weeks of age) used for in vivo experiments were purchased from The Jackson Laboratory and stored in the animal facility of Centro Nacional de Biotecnología (CNB-CSIC, Madrid). In vivo studies were approved by the Ethical Committee of Animal Experimentation (CEEA) of CNB-CSIC and by the competent authority of <italic>Comunidad de Madrid</italic> (PROEX 041.4/21). Animal procedures were conformed to international guidelines and to Spanish-European law.</p></sec></sec></body><back><sec sec-type="additional-information" id="s4"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Formal analysis, Investigation, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con3"><p>Conceptualization</p></fn><fn fn-type="con" id="con4"><p>Data curation, Methodology</p></fn><fn fn-type="con" id="con5"><p>Conceptualization, Methodology</p></fn><fn fn-type="con" id="con6"><p>Methodology</p></fn><fn fn-type="con" id="con7"><p>Methodology</p></fn><fn fn-type="con" id="con8"><p>Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con9"><p>Conceptualization, Data curation, Formal analysis, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con10"><p>Conceptualization, Data curation, Formal analysis, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con11"><p>Conceptualization, Resources, Data curation, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing - original draft, Project administration, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>In vivo studies were approved by the Ethical Committee of Animal Experimentation (CEEA) of CNB-CSIC and by the competent authority of Comunidad de Madrid (PROEX 041.4/21). Animal procedures were conformed to international guidelines and to Spanish-European law.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s5"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-95010-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s6"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files; source data files have been provided for Figures 1, 2 and 3.</p></sec><ack id="ack"><title>Acknowledgements</title><p>The research is supported by grants: PID2020-116393RB-I00, financed by MCIN/ AEI /10.13039/501100011033/and BFERO2020.04, financed by FERO foundation. AMP is supported by FPU18/03199JMGG from MCIN. We are grateful to the Proteomics and the Animal Facilities of CNB for peptide synthesis and their support.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bjerregaard</surname><given-names>AM</given-names></name><name><surname>Pedersen</surname><given-names>TK</given-names></name><name><surname>Marquard</surname><given-names>AM</given-names></name><name><surname>Hadrup</surname><given-names>SR</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Prediction of neoepitopes from murine sequencing data</article-title><source>Cancer Immunology, Immunotherapy</source><volume>68</volume><fpage>159</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1007/s00262-018-2254-5</pub-id><pub-id pub-id-type="pmid">30291365</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boegel</surname><given-names>S</given-names></name><name><surname>Castle</surname><given-names>JC</given-names></name><name><surname>Kodysh</surname><given-names>J</given-names></name><name><surname>O’Donnell</surname><given-names>T</given-names></name><name><surname>Rubinsteyn</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Bioinformatic methods for cancer neoantigen prediction</article-title><source>Progress in Molecular Biology and Translational Science</source><volume>164</volume><fpage>25</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1016/bs.pmbts.2019.06.016</pub-id><pub-id pub-id-type="pmid">31383407</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bulik-Sullivan</surname><given-names>B</given-names></name><name><surname>Busby</surname><given-names>J</given-names></name><name><surname>Palmer</surname><given-names>CD</given-names></name><name><surname>Davis</surname><given-names>MJ</given-names></name><name><surname>Murphy</surname><given-names>T</given-names></name><name><surname>Clark</surname><given-names>A</given-names></name><name><surname>Busby</surname><given-names>M</given-names></name><name><surname>Duke</surname><given-names>F</given-names></name><name><surname>Yang</surname><given-names>A</given-names></name><name><surname>Young</surname><given-names>L</given-names></name><name><surname>Ojo</surname><given-names>NC</given-names></name><name><surname>Caldwell</surname><given-names>K</given-names></name><name><surname>Abhyankar</surname><given-names>J</given-names></name><name><surname>Boucher</surname><given-names>T</given-names></name><name><surname>Hart</surname><given-names>MG</given-names></name><name><surname>Makarov</surname><given-names>V</given-names></name><name><surname>Montpreville</surname><given-names>VTD</given-names></name><name><surname>Mercier</surname><given-names>O</given-names></name><name><surname>Chan</surname><given-names>TA</given-names></name><name><surname>Scagliotti</surname><given-names>G</given-names></name><name><surname>Bironzo</surname><given-names>P</given-names></name><name><surname>Novello</surname><given-names>S</given-names></name><name><surname>Karachaliou</surname><given-names>N</given-names></name><name><surname>Rosell</surname><given-names>R</given-names></name><name><surname>Anderson</surname><given-names>I</given-names></name><name><surname>Gabrail</surname><given-names>N</given-names></name><name><surname>Hrom</surname><given-names>J</given-names></name><name><surname>Limvarapuss</surname><given-names>C</given-names></name><name><surname>Choquette</surname><given-names>K</given-names></name><name><surname>Spira</surname><given-names>A</given-names></name><name><surname>Rousseau</surname><given-names>R</given-names></name><name><surname>Voong</surname><given-names>C</given-names></name><name><surname>Rizvi</surname><given-names>NA</given-names></name><name><surname>Fadel</surname><given-names>E</given-names></name><name><surname>Frattini</surname><given-names>M</given-names></name><name><surname>Jooss</surname><given-names>K</given-names></name><name><surname>Skoberne</surname><given-names>M</given-names></name><name><surname>Francis</surname><given-names>J</given-names></name><name><surname>Yelensky</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification</article-title><source>Nature Biotechnology</source><volume>01</volume><elocation-id>e4313</elocation-id><pub-id pub-id-type="doi">10.1038/nbt.4313</pub-id><pub-id pub-id-type="pmid">30556813</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cable</surname><given-names>J</given-names></name><name><surname>Greenbaum</surname><given-names>B</given-names></name><name><surname>Pe’er</surname><given-names>D</given-names></name><name><surname>Bollard</surname><given-names>CM</given-names></name><name><surname>Bruni</surname><given-names>S</given-names></name><name><surname>Griffin</surname><given-names>ME</given-names></name><name><surname>Allison</surname><given-names>JP</given-names></name><name><surname>Wu</surname><given-names>CJ</given-names></name><name><surname>Subudhi</surname><given-names>SK</given-names></name><name><surname>Mardis</surname><given-names>ER</given-names></name><name><surname>Brentjens</surname><given-names>R</given-names></name><name><surname>Sosman</surname><given-names>JA</given-names></name><name><surname>Cemerski</surname><given-names>S</given-names></name><name><surname>Zavitsanou</surname><given-names>A-M</given-names></name><name><surname>Proia</surname><given-names>T</given-names></name><name><surname>Egeblad</surname><given-names>M</given-names></name><name><surname>Nolan</surname><given-names>G</given-names></name><name><surname>Goswami</surname><given-names>S</given-names></name><name><surname>Spranger</surname><given-names>S</given-names></name><name><surname>Mackall</surname><given-names>CL</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Frontiers in cancer immunotherapy-a symposium report</article-title><source>Annals of the New York Academy of Sciences</source><volume>1489</volume><fpage>30</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1111/nyas.14526</pub-id><pub-id pub-id-type="pmid">33184911</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castle</surname><given-names>JC</given-names></name><name><surname>Kreiter</surname><given-names>S</given-names></name><name><surname>Diekmann</surname><given-names>J</given-names></name><name><surname>Löwer</surname><given-names>M</given-names></name><name><surname>van de Roemer</surname><given-names>N</given-names></name><name><surname>de Graaf</surname><given-names>J</given-names></name><name><surname>Selmi</surname><given-names>A</given-names></name><name><surname>Diken</surname><given-names>M</given-names></name><name><surname>Boegel</surname><given-names>S</given-names></name><name><surname>Paret</surname><given-names>C</given-names></name><name><surname>Koslowski</surname><given-names>M</given-names></name><name><surname>Kuhn</surname><given-names>AN</given-names></name><name><surname>Britten</surname><given-names>CM</given-names></name><name><surname>Huber</surname><given-names>C</given-names></name><name><surname>Türeci</surname><given-names>O</given-names></name><name><surname>Sahin</surname><given-names>U</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Exploiting the mutanome for tumor vaccination</article-title><source>Cancer Research</source><volume>72</volume><fpage>1081</fpage><lpage>1091</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-11-3722</pub-id><pub-id pub-id-type="pmid">22237626</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>DS</given-names></name><name><surname>Mellman</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Oncology meets immunology: the cancer-immunity cycle</article-title><source>Immunity</source><volume>39</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2013.07.012</pub-id><pub-id pub-id-type="pmid">23890059</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeVette</surname><given-names>CI</given-names></name><name><surname>Andreatta</surname><given-names>M</given-names></name><name><surname>Bardet</surname><given-names>W</given-names></name><name><surname>Cate</surname><given-names>SJ</given-names></name><name><surname>Jurtz</surname><given-names>VI</given-names></name><name><surname>Jackson</surname><given-names>KW</given-names></name><name><surname>Welm</surname><given-names>AL</given-names></name><name><surname>Nielsen</surname><given-names>M</given-names></name><name><surname>Hildebrand</surname><given-names>WH</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>NetH2pan: a computational tool to guide MHC peptide prediction on murine tumors</article-title><source>Cancer Immunology Research</source><volume>6</volume><fpage>636</fpage><lpage>644</lpage><pub-id pub-id-type="doi">10.1158/2326-6066.CIR-17-0298</pub-id><pub-id pub-id-type="pmid">29615400</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duan</surname><given-names>F</given-names></name><name><surname>Duitama</surname><given-names>J</given-names></name><name><surname>Al Seesi</surname><given-names>S</given-names></name><name><surname>Ayres</surname><given-names>CM</given-names></name><name><surname>Corcelli</surname><given-names>SA</given-names></name><name><surname>Pawashe</surname><given-names>AP</given-names></name><name><surname>Blanchard</surname><given-names>T</given-names></name><name><surname>McMahon</surname><given-names>D</given-names></name><name><surname>Sidney</surname><given-names>J</given-names></name><name><surname>Sette</surname><given-names>A</given-names></name><name><surname>Baker</surname><given-names>BM</given-names></name><name><surname>Mandoiu</surname><given-names>II</given-names></name><name><surname>Srivastava</surname><given-names>PK</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity</article-title><source>Journal of Experimental Medicine</source><volume>211</volume><fpage>2231</fpage><lpage>2248</lpage><pub-id pub-id-type="doi">10.1084/jem.20141308</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hasegawa</surname><given-names>T</given-names></name><name><surname>Hayashi</surname><given-names>S</given-names></name><name><surname>Shimizu</surname><given-names>E</given-names></name><name><surname>Mizuno</surname><given-names>S</given-names></name><name><surname>Niida</surname><given-names>A</given-names></name><name><surname>Yamaguchi</surname><given-names>R</given-names></name><name><surname>Miyano</surname><given-names>S</given-names></name><name><surname>Nakagawa</surname><given-names>H</given-names></name><name><surname>Imoto</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Neoantimon: a multifunctional R package for identification of tumor-specific neoantigens</article-title><source>Bioinformatics</source><volume>36</volume><fpage>4813</fpage><lpage>4816</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btaa616</pub-id><pub-id pub-id-type="pmid">33123738</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hundal</surname><given-names>J</given-names></name><name><surname>Carreno</surname><given-names>BM</given-names></name><name><surname>Petti</surname><given-names>AA</given-names></name><name><surname>Linette</surname><given-names>GP</given-names></name><name><surname>Griffith</surname><given-names>OL</given-names></name><name><surname>Mardis</surname><given-names>ER</given-names></name><name><surname>Griffith</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>pVAC-Seq: a genome-guided in silico approach to identifying tumor neoantigens</article-title><source>Genome Medicine</source><volume>8</volume><elocation-id>11</elocation-id><pub-id pub-id-type="doi">10.1186/s13073-016-0264-5</pub-id><pub-id pub-id-type="pmid">26825632</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalbasi</surname><given-names>A</given-names></name><name><surname>Ribas</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Tumour-intrinsic resistance to immune checkpoint blockade</article-title><source>Nature Reviews. Immunology</source><volume>20</volume><fpage>25</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1038/s41577-019-0218-4</pub-id><pub-id pub-id-type="pmid">31570880</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Novello</surname><given-names>S</given-names></name><name><surname>Kowalski</surname><given-names>DM</given-names></name><name><surname>Luft</surname><given-names>A</given-names></name><name><surname>Gümüş</surname><given-names>M</given-names></name><name><surname>Vicente</surname><given-names>D</given-names></name><name><surname>Mazières</surname><given-names>J</given-names></name><name><surname>Rodríguez-Cid</surname><given-names>J</given-names></name><name><surname>Tafreshi</surname><given-names>A</given-names></name><name><surname>Cheng</surname><given-names>Y</given-names></name><name><surname>Lee</surname><given-names>KH</given-names></name><name><surname>Golf</surname><given-names>A</given-names></name><name><surname>Sugawara</surname><given-names>S</given-names></name><name><surname>Robinson</surname><given-names>AG</given-names></name><name><surname>Halmos</surname><given-names>B</given-names></name><name><surname>Jensen</surname><given-names>E</given-names></name><name><surname>Schwarzenberger</surname><given-names>P</given-names></name><name><surname>Pietanza</surname><given-names>MC</given-names></name><name><surname>Paz-Ares</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Pembrolizumab plus chemotherapy in squamous non-small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 study</article-title><source>Journal of Clinical Oncology</source><volume>41</volume><fpage>1999</fpage><lpage>2006</lpage><pub-id pub-id-type="doi">10.1200/JCO.22.01990</pub-id><pub-id pub-id-type="pmid">36735893</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O’Donnell</surname><given-names>TJ</given-names></name><name><surname>Rubinsteyn</surname><given-names>A</given-names></name><name><surname>Laserson</surname><given-names>U</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>MHCflurry 2.0: improved pan-allele prediction of MHC class I-presented peptides by incorporating antigen processing</article-title><source>Cell Systems</source><volume>11</volume><fpage>42</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/j.cels.2020.06.010</pub-id><pub-id pub-id-type="pmid">32711842</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schumacher</surname><given-names>TN</given-names></name><name><surname>Schreiber</surname><given-names>RD</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Neoantigens in cancer immunotherapy</article-title><source>Science</source><volume>348</volume><fpage>69</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1126/science.aaa4971</pub-id><pub-id pub-id-type="pmid">25838375</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tran</surname><given-names>E</given-names></name><name><surname>Robbins</surname><given-names>PF</given-names></name><name><surname>Rosenberg</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>“Final common pathway” of human cancer immunotherapy: targeting random somatic mutations</article-title><source>Nature Immunology</source><volume>18</volume><fpage>255</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1038/ni.3682</pub-id><pub-id pub-id-type="pmid">28198830</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vitiello</surname><given-names>A</given-names></name><name><surname>Zanetti</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Neoantigen prediction and the need for validation</article-title><source>Nature Biotechnology</source><volume>35</volume><fpage>815</fpage><lpage>817</lpage><pub-id pub-id-type="doi">10.1038/nbt.3932</pub-id><pub-id pub-id-type="pmid">28898209</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wert-Carvajal</surname><given-names>C</given-names></name><name><surname>Sánchez-García</surname><given-names>R</given-names></name><name><surname>Macías</surname><given-names>JR</given-names></name><name><surname>Sanz-Pamplona</surname><given-names>R</given-names></name><name><surname>Pérez</surname><given-names>AM</given-names></name><name><surname>Alemany</surname><given-names>R</given-names></name><name><surname>Veiga</surname><given-names>E</given-names></name><name><surname>Sorzano</surname><given-names>CÓS</given-names></name><name><surname>Muñoz-Barrutia</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Predicting MHC I restricted T cell epitopes in mice with NAP-CNB, a novel online tool</article-title><source>Scientific Reports</source><volume>11</volume><elocation-id>10780</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-021-89927-5</pub-id><pub-id pub-id-type="pmid">34031450</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>B</given-names></name><name><surname>Zhao</surname><given-names>W</given-names></name><name><surname>Su</surname><given-names>Z</given-names></name><name><surname>Gu</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>DeepHLApan: a deep learning approach for neoantigen prediction considering both HLA-peptide binding and immunogenicity</article-title><source>Frontiers in Immunology</source><volume>10</volume><elocation-id>2559</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2019.02559</pub-id><pub-id pub-id-type="pmid">31736974</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.95010.3.sa0</article-id><title-group><article-title>eLife Assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zaidi</surname><given-names>Neeha</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00za53h95</institution-id><institution>Johns Hopkins University</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Convincing</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Important</kwd></kwd-group></front-stub><body><p>Veiga et al demonstrate the importance of incorporating RNAseq and machine learning approaches for neoantigen prediction. The evidence is <bold>convincing</bold>, and these findings contribute <bold>important</bold> information towards the selection of neoantigens for personalized antitumor vaccination.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.95010.3.sa1</article-id><title-group><article-title>Reviewer #1 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>The authors of the study are trying to show that RNAseq can be used for neoantigen prediction and the machine learning approach to the prediction can reveal very useful information for the selection of neoantigens for personalized antitumor vaccination.</p><p>Strengths:</p><p>The authors demonstrated that RNA expression of a neoantigen is very important factor in the selection of peptides for the creation of personalized vaccines. They proved in vivo that in silico-predicted neoantigens can trigger antitumor response in mice.</p><p>Weaknesses:</p><p>The authors replied to my previous comment about the selection of the peptides for vaccination in the responses to reviewers, but didn't include that in the revised manuscript. I think all that information should be in the manuscript.</p><p>Here is the original comment: &quot;The selection of the peptides for vaccination is not clear. Some peptides were selected before and some after processing. What processing is also not clear. The authors didn't provide the full list of peptides before and after processing, please add those. And it wasn't clear that these peptides were previously published. Looking at the previously published table with peptide from B16 F10 (<ext-link ext-link-type="uri" xlink:href="https://www.nature.com/articles/s41598-021-89927-5/tables/3">https://www.nature.com/articles/s41598-021-89927-5/tables/3</ext-link>), there are other genes with high expression, e.g. Tab2, Tm9sf3 that have higher expression than Herc6, please clarify the choice.&quot;</p></body></sub-article><sub-article article-type="author-comment" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.95010.3.sa2</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mendez-Perez</surname><given-names>Almudena</given-names></name><role specific-use="author">Author</role><aff><institution>National Center for Biotechnology</institution><addr-line><named-content content-type="city">Madrid</named-content></addr-line><country>Spain</country></aff></contrib><contrib contrib-type="author"><name><surname>Acosta-Moreno</surname><given-names>Andres M</given-names></name><role specific-use="author">Author</role><aff><institution>National Center for Biotechnology</institution><addr-line><named-content content-type="city">Madrid</named-content></addr-line><country>Spain</country></aff></contrib><contrib contrib-type="author"><name><surname>Wert-Carvajal</surname><given-names>Carlos</given-names></name><role specific-use="author">Author</role><aff><institution>Centro Nacional de Biotecnología</institution><addr-line><named-content content-type="city">Madrid</named-content></addr-line><country>Spain</country></aff></contrib><contrib contrib-type="author"><name><surname>Ballesteros-Cuartero</surname><given-names>Pilar</given-names></name><role specific-use="author">Author</role><aff><institution>National Center for Biotechnology</institution><addr-line><named-content content-type="city">Madrid</named-content></addr-line><country>Spain</country></aff></contrib><contrib contrib-type="author"><name><surname>Sánchez-García</surname><given-names>Ruben</given-names></name><role specific-use="author">Author</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/052gg0110</institution-id><institution>University of Oxford</institution></institution-wrap><addr-line><named-content content-type="city">Oxford</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Macias</surname><given-names>Jose R</given-names></name><role specific-use="author">Author</role><aff><institution>National Center for Biotechnology</institution><addr-line><named-content content-type="city">Madrid</named-content></addr-line><country>Spain</country></aff></contrib><contrib contrib-type="author"><name><surname>Sanz-Pamplona</surname><given-names>Rebeca</given-names></name><role specific-use="author">Author</role><aff><institution>Catalan Institute of Oncology (ICO), Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL)</institution><addr-line><named-content content-type="city">L'Hospitalet de Llobregat</named-content></addr-line><country>Spain</country></aff></contrib><contrib contrib-type="author"><name><surname>Alemany</surname><given-names>Ramon</given-names></name><role specific-use="author">Author</role><aff><institution>IDIBELL-Institut Català d'Oncologia</institution><addr-line><named-content content-type="city">Barcelona</named-content></addr-line><country>Spain</country></aff></contrib><contrib contrib-type="author"><name><surname>Oscar Sorzano</surname><given-names>Carlos</given-names></name><role specific-use="author">Author</role><aff><institution>National Center of Biotechnology (CSIC)</institution><addr-line><named-content content-type="city">Madrid</named-content></addr-line><country>Spain</country></aff></contrib><contrib contrib-type="author"><name><surname>Munoz-Barrutia</surname><given-names>Arrate</given-names></name><role specific-use="author">Author</role><aff><institution>Universidad Carlos III de Madrid</institution><addr-line><named-content content-type="city">Madrid</named-content></addr-line><country>Spain</country></aff></contrib><contrib contrib-type="author"><name><surname>Veiga</surname><given-names>Esteban</given-names></name><role specific-use="author">Author</role><aff><institution>National Center for Biotechnology</institution><addr-line><named-content content-type="city">Madrid</named-content></addr-line><country>Spain</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews.</p><p><bold>Reply to Reviewer #1 (Public Review):</bold></p><p>The post-processing increases number of putative neoantigens. As shown in Author response image 1, this is done through data augmentation or “mutations” of individual amino acids in a sequence by their most similar amino acid in the BLOSUM62 embedding. If most of the mutations result in a positive prediction (which we binarize through a &gt;0.5 score) the sequence changes its prediction.</p><fig id="sa2fig1" position="float"><label>Author response image 1.</label><caption><title>Post-processing pipeline to increase the number of putative neoantigens.</title><p>Sequences can either be predicted using the forward method, for which a raw score is produced, or it can be introduced to a majority-vote prediction of the ensemble prediction of similar protein sequences.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95010-sa2-fig1-v1.tif"/></fig><p>In this article, we obtain the following candidates after post-processing.</p><table-wrap id="sa2table1" position="float"><label>Author response table 1.</label><caption><title>Sequence symbol gene prediction fragments per kilobase million (FPKM).</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="bottom">PPTARMMFSGLA Wiz</th><th valign="bottom">ENSMUSG000000024050 1</th><th valign="bottom">16,7001</th></tr></thead><tbody><tr><td align="left" valign="bottom">NKVVMEYENLEK Pnp</td><td align="left" valign="bottom">ENSMUSG00000115338 1</td><td align="char" char="." valign="bottom">3,03912</td></tr><tr><td align="left" valign="bottom">TFVYPTIFPLRE Lrrc28</td><td align="left" valign="bottom">ENSMUSG00000030556 1</td><td align="char" char="." valign="bottom">0,941842</td></tr><tr><td align="left" valign="bottom">SQAWTHPPGVVN Adar</td><td align="left" valign="bottom">ENSMUSG00000027951 1</td><td align="char" char="." valign="bottom">0</td></tr><tr><td align="left" valign="bottom">KASGFRYNVLSC Nr1h2</td><td align="left" valign="bottom">ENSMUSG00000060601 1</td><td align="char" char="." valign="bottom">0</td></tr><tr><td align="left" valign="bottom">FVPGPSFWGLVN Car11</td><td align="left" valign="bottom">ENSMUSG00000003273 1</td><td align="char" char="." valign="bottom">0</td></tr></tbody></table></table-wrap><p>As mentioned, the prediction column shows a binary label. The full list contained 402 sequences did not include any other sequences that met the majority vote criteria.</p><p>As noted by the reviewer, the Table 3 of our original paper includes the scores of the direct prediction, which has four sequences in common with the post-processing criteria (*Pnp, *Adar, *Lrrc28 and *Nr1h2). * indicates the mutated form of the peptide, i.e neoantigen.</p><p>We selected the top 4 predicted antigens present both by direct prediction and after post-processing; (*Pnp, *Adar, *Lrrc28 and *Nr1h2) (Wert-Carvajal et al. 2021), but we encountered difficulty in synthesizing, *Nr1h2 (Mutated Nr1h2), and thus it could not be included in the study.</p><p>We also decided to evaluate the immunogenicity of *Wiz, which was identified as a potential TNA only after postprocessing. *Wiz exhibited lower levels of immunogenicity compared to *Pnp, *Adar, and *Lrrc28. However, unlike these, *Wiz is highly expressed in the tumor, and vaccination with *Wiz provided the strongest protection levels. These findings led us to incorporate post-processingg into the NAPCNB platform.</p><p>We chose *Herc6 as a mutated antigen predicted not to be a TNA over other candidates because its expression in the tumor was similar to that of *Wiz.</p><p>Depending on the experiment we used 4 or 5 animals per group (this is now clarified in the revised version).</p><p>The software used for statistical analysis was GraphPad Prism.</p><p><bold>Reply to Reviewer #2 (Public Review):</bold></p><p>This is true, binding affinity does not always predict immune responses but in most cases, high affinity peptides are immunogenic. There are of course other parameters that drive the effective priming of tumor-reactive CD8+ T cells through antigen crosspresentation, but the mechanisms of antigen presentation are yet not completely understood. High affinity peptides are desirable as good candidates in neoantigen-based vaccines.</p><p>Other comments of the reviewers</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Recommendations For The Authors):</bold></p><p>- Please decipher all abbreviations when they appear for the first time, e.g. NAP-CNB, PBS, CFA, FIA, and so on.</p></disp-quote><p>Done in the revised version.</p><disp-quote content-type="editor-comment"><p>- Please be consistent with the capitalization of gene names (WIZ vs Wiz, TRP2 vs Trp2, and so on), and why there is an asterisk.</p></disp-quote><p>Done in the revised version.</p><disp-quote content-type="editor-comment"><p>- Please be clear about where you use cell lines or mice as a model. It's not clear.</p></disp-quote><p>All work is done in mice, or cells isolated from vaccinated mice.</p><disp-quote content-type="editor-comment"><p>- Why there is an asterisk in front of gene names?</p></disp-quote><p>Explained in the revised version; The * indicates the peptides that are the mutated version.</p><disp-quote content-type="editor-comment"><p>- Please add a reference for the following statement in the Introduction: &quot;However, the response rates of these therapies remain low and relapses are common.&quot;</p></disp-quote><p>Done in the revised version.</p><disp-quote content-type="editor-comment"><p>- Also please add a reference for the use of TRP2 as a positive control.</p></disp-quote><p>Done in the revised version.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Recommendations For The Authors):</bold></p><p>- It may be helpful to validate a larger pool of antigens. This is not necessary however and could be done in a follow-up study.</p></disp-quote><p>We are doing it for other studies with excellent results.</p><disp-quote content-type="editor-comment"><p>- The negative PBS control should be included in Figure 1.</p></disp-quote><p>Done in the modified figure 1C in the revised version.</p><disp-quote content-type="editor-comment"><p>- Stats should be clearly indicated in Figure 2.</p></disp-quote><p>Done in the revised version.</p><disp-quote content-type="editor-comment"><p>- Some nuances should be discussed. Is a threshold of neoantigen expression required or is there a correlation with tumor control? On the flip side, these neoantigens that are not likely to elicit immune responses but are highly expressed are also not likely to mediate tumor control.</p></disp-quote><p>These points have been discussed. Based on our data, strategies for designing antitumor therapies should prioritize antigens that are highly expressed in tumors, even if they are not the most immunogenic. However, it is worth noting that even low-expressed antigens can still elicit an antitumor immune response. If possible one should define strategies attacking multiple antigens in order to minimize tumor scape. Whenever possible, strategies should be developed to target multiple antigens simultaneously, aiming to minimize tumor escape.</p><disp-quote content-type="editor-comment"><p>- This study focuses on CD8 T cell responses but CD4s are also important in tumor control. This could be mentioned in the discussion.</p></disp-quote><p>This is true, but this article focuses on validating a platform that predicts the antigenicity of antigens presented in the context of MHC-I.</p><disp-quote content-type="editor-comment"><p>- Ideally, we would want to see that these responses are not elicited with adjuvant alone as an additional control.</p></disp-quote><p>The non-vaccinated control animals received PBS and adjuvant. This clarification has now been included in the text.</p></body></sub-article></article>